Skip to main content
Caplight Logo









Rondo Therapeutics

Rondo Therapeutics

Private
Hayward, CaliforniaHealthcare & Life Scienceshttps://www.rondotx.com/

Last Round

Series A

Mar 2, 2022

Total Funding Raised

$67M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Rondo Therapeutics is a biotechnology company that develops bispecific therapeutic antibodies aimed at modulating immune system activation to combat cancer, particularly in solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

immuno-oncologybispecific antibodysolid tumorsco-stimulatory therapycancer immunotherapyclinical-stage biotechbiotech drug discoveryCD28Nectin-4NGSnext-generation sequencingbiopharma R&Ddrug pipelineclinical trialsantibody engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rondo Therapeutics Comparables

Compare Rondo Therapeutics with similar companies based on industry and business-model similarity.

Rondo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Marengo Therapeutics
82%
Amgen
75%
Aktis Oncology
73%

Rondo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 2, 2022

Key People

Founding team and executive leadership

Jennifer Isacoff McNealey

Consulting Chief Financial Officer

Executive Team

Rondo Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 62% MoM, reaching 2.8K.

  • Jan 1, 2025

    Advanced first oncology asset into clinical trials in 2025.

Rondo Therapeutics Filings

Explore SEC and related filing metadata, where available.

Rondo Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Rondo Therapeutics's valuation, stock price, and market status.

Is Rondo Therapeutics a public or private company?

Rondo Therapeutics is a private company.

What is the current stock price of Rondo Therapeutics?

Rondo Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Rondo Therapeutics worth (valuation)?

Valuation information for Rondo Therapeutics is not publicly available.

Can I buy Rondo Therapeutics stock?

Rondo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Rondo Therapeutics's last funding round?

Rondo Therapeutics's most recent funding round was Series A on March 2, 2022.

Who are the main investors in Rondo Therapeutics?

Key investors in Rondo Therapeutics include Canaan Partners, Red Tree Venture Capital.

Will Rondo Therapeutics IPO soon?

No public IPO plans have been announced for Rondo Therapeutics.

How can I track Rondo Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Rondo Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHayward, California
Employee Range23
Year Founded2020
Last FundingMar 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?